IRG1-IN-1

• CAT Number: I042626
• CAS Number: 2407652-42-8
• Molecular Formula: C18H15FO4
• Molecular Weight: 314.31
• Purity: ≥95%
• Synonyms: (3Z)-2-benzyl-3-[(4-fluorophenyl)methylidene]butanedioic acid
• InChI: InChI=1S/C18H15FO4/c19-14-8-6-13(7-9-14)11-16(18(22)23)15(17(20)21)10-12-4-2-1-3-5-12/h1-9,11,15H,10H2,(H,20,21)(H,22,23)/b16-11-
• InChIKey: DZXOXUPVMSOERA-WJDWOHSUSA-N
• SMILES: C1=CC=C(C=C1)CC(C(=CC2=CC=C(C=C2)F)C(=O)O)C(=O)O

IRG1-IN-1 is an itaconic acid derivative. IRG1-IN-1 can inhibit immune-responsive gene 1 (IRG1) activity. IRG1-IN-1 can be used for the research of cancer, inflammation and autoimmune diseases[1].
IRG1-IN-1(compound 6) (0.5 mM; 2 mM) reduces production of itaconic acid and the secretion of TNFα from LPS-stimulated human monocyte derived macrophages (hMDMs) [1].
IRG1-IN-1 (0.5 mM; 1 mM) inhibits the proliferation of C-IRG1-9 rat glioma cells[1].
IRG1-IN-1(10 nM) increases proliferation of TCR-activated hCD8+ T cells[1].
IRG1-IN-1(10μM) shows depletion of trimethylation of histone 3 at lysine 4 (H3K4me3) in CR-activated hCD8+ T cells[1].
IRG1-IN-1 (compound 6) (i.p.; 0.2 mg/kg; 27 days) shows antitumor effect in C57BL/6 mice[1].

Reference

[1]. Adonia Papathanassiu, et al. Compositions and methods of using itaconic acid derivatives. Patent. US20210261495A1.